tradingkey.logo

Applied Therapeutics Inc <APLT.OQ> expected to post a loss of 19 cents a share - Earnings Preview

ReutersMay 5, 2025 1:31 PM
  • Applied Therapeutics Inc APLT.OQ APLT.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The New York City-based company is expected to report a 2,312.3% increase in revenue to $4.583 million from $190 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Applied Therapeutics Inc is for a loss of 19 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 9.1% in the last three months. ​

  • Wall Street's median 12-month price target for Applied Therapeutics Inc is $2.50​, above​ its last closing price of $0.46. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.18

0.33

Beat

285.9

Sep. 30 2024

-0.16

-0.16

-0.48

Missed

-203.8

Jun. 30 2024

-0.15

-0.16

0.02

Beat

112.2​

Mar. 31 2024

-0.16

-0.16

-0.67

Missed

-320.1

​​Dec. 31 2023

-0.20

-0.23

-0.34

Missed

-49.1

Sep. 30 2023

-0.23

-0.26

-0.47

Missed

-81.2​

Jun. 30 2023

-0.17

-0.26

-0.37

Missed

-39.6

Mar. 31 2023

-0.27

-0.31

-0.18

Beat

41.3

This summary was machine generated May 5 at 13:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI